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Laplace’s law, which can be used to estimate myocardial wall stress(σ) from intraventricular pressure (LVP), radius of curvature (R),and wall thickness (h), has long been recognized as a fundamentalphysical principle in understanding cardiac function in health anddisease: σ = LVP · R/h. On the basis of this law, the enlarged cham-ber radius of the chronically failing heart exposes myocytes to
increased systolic wall stress. This leads to cellular and chamber hypertrophy,
which, in an adaptive process, acts to renormalize wall stress.1 As the chamber con-
tinues to dilate over time, the limits of hypertrophy appear to be reached so that wall
stress ultimately increases. This increased afterload further impairs the ability of the
already weakened myocytes to shorten, and cardiac performance deteriorates.
Globally referred to as ventricular remodeling, this process is partially preventable
and reversible as demonstrated in studies of angiotensin-converting enzyme
inhibitors,2 β-blockers,3 and during hemodynamic unloading by prolonged support
with a left ventricular assist device.4
Several surgical therapies, such as the Myocor ventricular shape change device
(Myocor, Inc, Plymouth, Minn), described in this issue by McCarthy and col-
leagues,5 are being developed for treating heart failure by physically remodeling the
dilated heart. Stress reduction via Laplace’s law is usually sited as the rationale for
these therapies. The Batista procedure6 (partial left ventriculectomy for patients
with idiopathic cardiomyopathy) is an important predicate example. Despite initial
enthusiasm, clinical studies showed that although estimated wall stress was
reduced, a majority of patients did not experience improved hemodynamics or clin-
ical status in the long term.7 In my opinion, one limitation in thinking about this
procedure was the focus on its potentially beneficial effects on wall stress to the
exclusion of considering its effects on overall pump function. Specifically, the
effects of myocardial resection on diastolic ventricular properties were under-appre-
ciated. When expressed in terms of end-systolic and end-diastolic pressure-volume
relationships (ESPVR and EDPVR, respectively), theory predicted8,9 and clinical
research later showed10 that despite the potentially beneficial effects on systolic
properties of shifting the ESPVR leftward (increased chamber contractility), the
Batista procedure was also associated with counteracting effects on diastole. These
were manifest as similar, or even greater, leftward shifts of the EDPVR with a net
result of little net benefit on overall left ventricular pumping capacity (Figure 1, A).
Hypothetically, it would be more desirable for a therapy to cause a larger leftward
shift in the ESPVR than in the EDPVR (Figure 1, B), which would result in a
greater ventricular pumping capacity. Furthermore, we argued that changes in ejec-
tion fraction resulting from reductions in end-diastolic volume without changes in
stroke volume are not indicative of improved systolic function as they are in the set-
ting of standard inotropic therapy.8
McCarthy and colleagues, who played a pivotal role in the systematic clinical
evaluation of the Batista operation,11 have not abandoned the concept that radius of
curvature reduction can have a favorable impact on ventricular function. The inves-
tigators used struts (Myosplint; Myocor, Inc) placed across the ventricle to pull
opposing sides of the chamber together to alter ventricular shape and functionally
separate the chamber into two lobes, each with a smaller radius than the original
heart.5 An easy to understand explanation of how Laplace’s law predicts systolic
wall stress reduction by this shape change therapy is provided by the authors. This
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concept is also supported by more sophisticated computa-
tional model analysis of the same concept performed by
other investigators.12
Experimentally, McCarthy and associates show that, as
intended, the Myosplint device reduces ventricular end-
diastolic volume, end-systolic volume, and wall stress while
increasing ejection fraction; these effects are sustained to
the maximum time investigated, 1 month. However, there
were no significant changes in cardiac output, end-diastolic
pressure, or mean arterial pressure. These data indicate that
there are leftward shifts (smaller volumes at similar pres-
sures) in both ESPVR and EDPVR and furthermore suggest
that the shifts of these relationships are likely to be relative-
ly balanced so that there is little net effect on overall pump
function (as in Figure 1, A). With no acute or possibly even
chronic hemodynamic benefit, pivotal questions include
whether the Myosplint device actually resulted in regression
of hypertrophy (wall thickness and heart mass data would
be of interest) and whether any such changes would trans-
late into clinically meaningful effects on patient symptoms,
disease progression, and/or mortality. The latter are difficult
issues to address in preclinical studies.
As noted above, several forms of surgical therapies are
being investigated to physically remodel the failing heart,
including other passive devices13 and resection of akinetic
scars.14 There is a need to better define the effects of such
procedures on a broad range of mechanical and biochemi-
cal properties of the heart; consideration of effects on wall
stress alone may not reveal the entire picture. The impor-
tance of improved understanding stems at least in part
from the need for physicians considering referring their
patients for clinical trials to be able to assess the potential
that a surgical heart failure therapy with little (if any) acute
hemodynamic benefits will ultimately translate into clini-
cal benefits. Could this be the case for a therapy that
changes the shape of the failing heart? If such benefits
were confirmed by careful clinical investigation, surgeons
could have a means of meaningfully affecting the heart
failure epidemic and change the shape of heart failure
treatment in the future.
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Figure 1. Ventricular pump properties are typically represented by
ESPVR and EDPVR. In heart failure (red) both systolic and diastolic
curves are shifted toward significantly larger volumes compared
with normal (gray), a manifestation of ventricular remodeling. It
was shown previously that with the Batista procedure (blue), and
possibly for the Myosplint device, there is a rightward shift of the
EDPVR that is slightly greater than the shift in the ESPVR (A),
resulting in little change in net ventricular pump function as
shown by the pressure-volume loops with similar stroke volumes
at comparable end-diastolic and aortic pressures. This would
contrast with a hypothetical therapy that would induce a greater
leftward shift of the ESPVR than EDPVR and cause an increase in
net pumping capacity (B), as shown by the pressure-volume loop
(blue), with significantly increased stroke volume compared with
the heart failure state (red) at comparable end-diastolic and aor-
tic pressures. 
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